{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV+13&page=2", "query": { "intervention": "PCV 13", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCV+13&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-18T16:23:30.881Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06855160", "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chickenpox" ], "interventions": [ { "name": "Candidate varicella vaccine", "type": "BIOLOGICAL" }, { "name": "Marketed varicella vaccine", "type": "BIOLOGICAL" }, { "name": "MMR vaccine", "type": "BIOLOGICAL" }, { "name": "Hepatitis A vaccine", "type": "BIOLOGICAL" }, { "name": "PCV (pneumococcal conjugate vaccine) 13", "type": "BIOLOGICAL" }, { "name": "PCV 20", "type": "BIOLOGICAL" }, { "name": "Vaxneuvance", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 911, "start_date": "2025-04-17", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 13, "location_summary": "Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Sherman Oaks", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855160" }, { "nct_id": "NCT03039491", "title": "Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "HIV Lipodystrophy", "Aging" ], "interventions": [ { "name": "Pneumococcal polysaccharide vaccine 23 valent", "type": "BIOLOGICAL" }, { "name": "13 valent conjugated pneumococcal vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 160, "start_date": "2015-09-01", "completion_date": "2020-03-30", "has_results": false, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03039491" }, { "nct_id": "NCT04241094", "title": "Teaching Loved Ones to Help Veterans Optimize Their PTSD Care and Healing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Posttraumatic Stress Disorder" ], "interventions": [ { "name": "Loved one assisted treatment", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-11-02", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 3, "location_summary": "Decatur, Georgia • Ann Arbor, Michigan • Minneapolis, Minnesota", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04241094" }, { "nct_id": "NCT03207750", "title": "This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rotavirus Infection", "Rotavirus Vaccines" ], "interventions": [ { "name": "Rotarix", "type": "BIOLOGICAL" }, { "name": "Pediarix", "type": "BIOLOGICAL" }, { "name": "Hiberix", "type": "BIOLOGICAL" }, { "name": "Prevenar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Weeks", "maximum_age": "12 Weeks", "sex": "ALL", "summary": "6 Weeks to 12 Weeks" }, "enrollment_count": 1280, "start_date": "2017-09-14", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Daly City", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207750" }, { "nct_id": "NCT04398706", "title": "Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pneumococcal Immunisation", "Diphtheria Immunisation", "Tetanus Immunisation", "Pertussis Immunisation", "Hepatitis B Immunisation", "Haemophilus Influenzae Type b Immunisation", "Polio Immunisation", "Measles Immunisation", "Rubella Immunisation", "Varicella Immunisation", "Mumps Immunisation" ], "interventions": [ { "name": "Pneumococcal Conjugate Vaccine formulation 1", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine formulation 2", "type": "BIOLOGICAL" }, { "name": "Pneumococcal Conjugate Vaccine formulation 3", "type": "BIOLOGICAL" }, { "name": "Varicella Virus Vaccine Live", "type": "BIOLOGICAL" }, { "name": "Measles, Mumps, and Rubella Virus Vaccine Live", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]", "type": "BIOLOGICAL" }, { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate)", "type": "BIOLOGICAL" }, { "name": "Rotavirus Vaccine, Live, Oral, Pentavalent", "type": "BIOLOGICAL" }, { "name": "Hepatitis B Vaccine* [Recombinant] *as applicable", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "15 Months", "sex": "ALL", "summary": "42 Days to 15 Months" }, "enrollment_count": 852, "start_date": "2020-05-22", "completion_date": "2023-08-10", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 49, "location_summary": "Jonesboro, Arkansas • Bellflower, California • Huntington Park, California + 41 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04398706" }, { "nct_id": "NCT03439657", "title": "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Herpes Zoster" ], "interventions": [ { "name": "HZ/su vaccine GSK1437173A", "type": "BIOLOGICAL" }, { "name": "Prevenar13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 913, "start_date": "2018-04-12", "completion_date": "2020-03-03", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 3, "location_summary": "Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina", "locations": [ { "city": "Marlborough", "state": "Massachusetts" }, { "city": "Salisbury", "state": "North Carolina" }, { "city": "Spartanburg", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439657" }, { "nct_id": "NCT03035331", "title": "Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Aggressive Non-Hodgkin Lymphoma", "Indolent Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Cryosurgery", "type": "PROCEDURE" }, { "name": "Dendritic Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2017-08-15", "completion_date": "2022-09-10", "has_results": true, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03035331" }, { "nct_id": "NCT03942328", "title": "Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Pheresis", "type": "PROCEDURE" }, { "name": "Pneumococcal 13-valent Conjugate Vaccine", "type": "BIOLOGICAL" }, { "name": "Therapeutic Autologous Dendritic Cells", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Esophagogastroduodenoscopy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2019-09-19", "completion_date": "2031-02-28", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03942328" }, { "nct_id": "NCT03480802", "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumococcal Infections" ], "interventions": [ { "name": "V114", "type": "BIOLOGICAL" }, { "name": "Prevnar 13™", "type": "BIOLOGICAL" }, { "name": "PNEUMOVAX™23", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2018-07-06", "completion_date": "2020-01-17", "has_results": true, "last_update_posted_date": "2022-05-05", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 4, "location_summary": "Orlando, Florida • West Palm Beach, Florida • Houston, Texas", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03480802" }, { "nct_id": "NCT01702428", "title": "Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rubella", "Measles", "Mumps" ], "interventions": [ { "name": "Priorix", "type": "BIOLOGICAL" }, { "name": "M-M-R II", "type": "BIOLOGICAL" }, { "name": "Varivax", "type": "BIOLOGICAL" }, { "name": "Havrix", "type": "BIOLOGICAL" }, { "name": "Prevnar 13", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Months", "maximum_age": "15 Months", "sex": "ALL", "summary": "12 Months to 15 Months" }, "enrollment_count": 5016, "start_date": "2012-11-09", "completion_date": "2015-04-16", "has_results": true, "last_update_posted_date": "2019-11-25", "last_synced_at": "2026-09-18T16:23:30.881Z", "location_count": 62, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Daly City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01702428" } ] }